Moberg Pharma
Moberg Pharma: No surprises in the European study (Redeye)
2020-06-25 09:09
Redeye maintains its base case on Moberg Pharma, in which we calculated with MOB-015 achieving non-inferiority in the European study, sufficient for registration in Europe.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se